# Washington University School of Medicine: Phase 1 study closed enrollment, 9 enrolled (B Cell Lymphoma, Aggressive Lymphoma)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | Washington University School of Medicine |
| Sponsor type | Academic and hospital |
| Study | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma |
| NCT ID | NCT05412290 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | B Cell Lymphoma; Aggressive Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Transformed Lymphoma; Follicular Lymphoma Grade 3 |
| Intervention types | drug |
| Target enrollment | 9 |
| Site countries | United States |
| Posted | 2022-06-09 |
| Planned start | 2022-12-22 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-13 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05412290). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.